Comprehensive Metabolic Blood Panel: IDR 2,500,000 (approximately USD 150, SGD 210, GBP 118) Ozempic (semaglutide) monthly: from IDR 4,500,000 (titration doses 0.25-1mg) to IDR 6,500,000 (maintenance 2mg) approximately USD 270-390 / SGD 380-550 / GBP 215-310 prescribed for diabetic patients Wegovy (semaglutide 2.4mg) monthly: IDR 7,500,000 (approximately USD 450 / SGD 635 / GBP 355) Mounjaro (tirzepatide) monthly: IDR 6,800,000-8,500,000 depending on dose (approximately USD 410-510 / SGD 575-720 / GBP 325-405) All medications are BPOM-registered and sourced through authorised official Indonesian distributors only

For IBS-like discomfort more broadly, the 2021 American College of Gastroenterology clinical guideline on IBS made a conditional recommendation against the use of probiotics for the treatment of global IBS symptoms, citing very low quality of evidence and substantial heterogeneity across strains, doses, and outcomes.[6] The ACG position is the strongest authoritative reading available
The neurotrophin effects begin accumulating, potentially enhancing the peptides benefits over time
(15983093) Disadvantage: D10W takes slightly longer to give, so it may be less useful for patients with profound symptoms who need immediate treatment (e.g., seizure, coma)